Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
News Oct 24, 2007
The first collaboration project under the agreement was announced in December 2005, and a second project was entered into in March 2007. The two programmes utilize Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry, and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech.
Commenting on the extended agreements, Dr. Christopher Ashton, Argenta’s Chief Executive Officer, said, “We are delighted that Genentech has chosen to extend the collaboration for another two years. The two projects have made excellent progress and a good working relationship has been established between both teams of scientists over the past two years.
We believe this extension illustrates Argenta’s key strengths and continued commitment to deliver high quality, time- and cost-effective integrated drug discovery services and expertise. We very much look forward to continuing and growing our successful collaboration with Genentech.”
Financial terms of the deal, which incorporates a number of funded FTEs at Argenta for the next two years, were not disclosed. The agreement provides further options to expand the relationship.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE